Clinical trialPhase 3Unknown
Gemcitabine or Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer
Gemcitabine vs Gemcitabine + Cisplatin in the Treatment of Advanced Pancreatic Cancer (Stage II III IV)
- Outcome
- Outcome unknown
- Phase
- Phase 3
- Status
- Unknown
- Study type
- Interventional
- Start
- April 2002
- Expected end
- September 2009
- Enrollment
- 400 participants
- Sites
- 45
- Primary outcomes
- overall survival
- Sponsor
- Network
- Results posted
- No
- Last update
- 23 December 2008
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to evaluate the impact of the addition of cisplatin to gemcitabine in the treatment of patients with inoperable advanced pancreatic cancer.
Papers 1
- Registry-listed results paperRandomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment… DOI 10.1200/jco.2009.25.4433↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.